Novocure Ltd (NVCR) - Total Liabilities
Based on the latest financial reports, Novocure Ltd (NVCR) has total liabilities worth $457.21 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Novocure Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Novocure Ltd - Total Liabilities Trend (2013–2025)
This chart illustrates how Novocure Ltd's total liabilities have evolved over time, based on quarterly financial data. See NVCR free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Novocure Ltd Competitors by Total Liabilities
The table below lists competitors of Novocure Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kansai Nerolac Paints Limited
NSE:KANSAINER
|
India | Rs18.86 Billion |
|
LANXESS AG UNSP.ADR 1/5
F:LX9B
|
Germany | €4.28 Billion |
|
Qingdao Baheal Medical INC.
SHE:301015
|
China | CN¥5.67 Billion |
|
Shanghai Milkground Food Tech Co Ltd
SHG:600882
|
China | CN¥4.05 Billion |
|
Zhejiang Jingxin Pharmaceutical Co Ltd
SHE:002020
|
China | CN¥1.93 Billion |
|
Tyra Biosciences Inc
NASDAQ:TYRA
|
USA | $23.43 Million |
|
Bob's Discount Furniture, Inc.
NYSE:BOBS
|
USA | $815.06 Million |
|
Nuvation Bio Inc
NYSE:NUVB
|
USA | $290.68 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Novocure Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Novocure Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.38 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Novocure Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Novocure Ltd (2013–2025)
The table below shows the annual total liabilities of Novocure Ltd from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $463.86 Million | -47.32% |
| 2024-12-31 | $880.61 Million | +12.37% |
| 2023-12-31 | $783.63 Million | +4.42% |
| 2022-12-31 | $750.48 Million | +2.95% |
| 2021-12-31 | $729.00 Million | +26.68% |
| 2020-12-31 | $575.46 Million | +119.93% |
| 2019-12-31 | $261.66 Million | +15.00% |
| 2018-12-31 | $227.53 Million | +49.96% |
| 2017-12-31 | $151.73 Million | +8.59% |
| 2016-12-31 | $139.74 Million | +147.25% |
| 2015-12-31 | $56.52 Million | +182.57% |
| 2014-12-31 | $20.00 Million | +16.75% |
| 2013-12-31 | $17.13 Million | -- |
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more